비교리스트

 카트 문의
시장보고서
상품코드
1419021

세계 BCMA 표적요법 시장 : 유형별, 암별, 최종사용자별, 국가별, 지역별: 산업 분석 : 시장 규모, 시장 점유율 및 예측(2024년-2032년)

Bcma Targeted Therapies Market, By Type, By Cancer, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 299 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

BCMA 표적요법 시장 규모는 2023년 90억 1,000만 달러로 평가되었고 2024년부터 2032년까지 복합 연간 성장률(CAGR) 20.5%로 확대될 전망입니다.

BCMA 표적 치료 시장 - 시장 역학

다발성 골수종의 재발증 사례 증가는 B 세포 성숙 항원(BCMA) 표적 치료 시장의 성장을 가속할 것으로 예상된다.

표적 치료 등의 BCMA 표적 요법은 BCMA를 발현하는 암세포에 특이적으로 초점을 맞추는 것으로 보다 정확한 방법을 제공합니다. 이 접근법은 보다 효과적이고 해롭지 않은 치료를 제공할 수 있어 언메트 메디컬 요건을 충족시킬 수 있습니다. 미국 임상종양학회에 따르면 2023년에는 미국에서 추정 35,730명(남성 19,860명, 여성 15,870명)의 성인이 다발성 골수종으로 진단됩니다. 세계에서는 2020년에 추정된 176,404명이 다발성 골수종으로 진단되었습니다. 게다가, 다발성 골수종의 분자 및 유전적 기반의 해명이 진행됨으로써, 새로운 치료 표적이 확인되고, 보다 강력한 BCMA 표적 요법이 개발될 가능성이 있습니다. 그러나 이러한 치료법의 비용이 높으면 시장 성장을 방해할 수 있다는 점에 유의하는 것이 중요합니다.

BCMA 표적 치료 시장 - 세분화 분석 :

BCMA 표적 요법 세계 시장은 유형, 암, 최종 사용자, 지역에 따라 구분됩니다.

시장은 유형에 따라 세 가지 범주로 나뉩니다 . 시장은 이중특이적 항체, 항체 약물 복합체, 키메라 항원 수용체 T 세포의 세 가지 유형으로 분류됩니다. 다발성 골수종 세포는 형질 세포를 침범하는 암의 일종으로 표면에 BCMA라고 불리는 단백질을 발현하고 있습니다. CAR-T 세포요법은 암세포를 식별하고 공격하는 키메라 항원 수용체(CAR)를 발현하도록 환자 자신의 T세포를 개변하는 면역요법 접근법입니다.

시장은 암의 유형에 따라 세 가지 그룹으로 나뉩니다. 간암, 호흡기 암, 뇌종양 등. B세포성숙항원(BCMA) 표적요법은 주로 형질세포에 영향을 주는 암의 일종인 다발성 골수종의 치료에 이용되어 왔습니다. BCMA는 다발성 골수종 세포의 표면에 존재하기 때문에 치료 중재의 좋은 표적이됩니다.

시장은 최종 사용자 별로 병원과 암연구소의 두 가지로 분류됩니다 . 이 시장은 주로 병원 부문이 지배하고 있습니다. 환자 치료 및 지원 서비스를 개선하기 위해 병원은 BCMA 표적 치료의 잠재적인 부작용 관리와 치료를 받는 환자에게 종합적인 치료를 제공하는 데 주력해야 할 수도 있습니다. 병원은 암 치료의 실시에 관한 규제 요건을 준수하고, 의료 당국이 정한 안전성과 유효성의 기준에 따른 프로토콜을 확실히 실시하는 것이 매우 중요합니다.

BCMA 표적 치료 시장 - 지리적 인사이트

지리적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동, 아프리카 등 다양한 지역으로 퍼져 있습니다. 이 지역은 사업 활동을 수행하는 국가에 따라 추가로 구분됩니다. 다발성 골수종에 대한 혁신적인 치료법의 연구개발에 대한 투자가 증가하고 있기 때문에 시장의 성장은 북미가 독점할 것으로 예상됩니다. 미국은 임상 연구의 주요 거점으로 다발성 골수종을 포함한 다양한 질병에 대한 수많은 임상시험이 실시되고 있습니다. 저명한 연구기관, 학술의료센터, 바이오테크놀러지 기업이 존재함으로써 임상시험을 실시하기 위한 강력한 인프라가 구축되어 새로운 치료법의 개발이 촉진되고 있습니다. 국민의료비에 따르면 미국(US)의 의료·건강 연구개발(R&D) 투자는 크게 증가했으며, 2020년에는 2019년부터 11.1% 증가한 2,451억 달러에 달했습니다. 민간인 R&D 생태계의 성장률은 2020년에 변화를 보였으나 이는 COVID-19 팬데믹에 대한 대응과 그 영향으로 인한 것으로 보입니다.

BCMA 표적 치료 시장 - 경쟁 구도:

BCMA 표적 치료 시장은 역동적인 경쟁 구도를 특징으로 하며 수많은 제약 기업과 생명공학 기업들이 이러한 치료제 개발에 적극적으로 참여하고 있습니다. 이러한 치료제는 다발성 골수종, 특히 재발 또는 다른 치료 옵션에 저항성을 보이는 환자에 대한 임상적 효능을 입증합니다. 현재 많은 기업들이 전임상 단계와 임상 단계 모두에서 BCMA를 표적으로 하는 치료법의 개발에 종사하고 있으며, BCMA 단체의 치료법으로서 또는 다른 약제와의 병용 요법으로서 개발되고 있다. 예를 들면, 2023년 1월 31일, 세포 및 유전자 치료를 전문으로 하는 임상 단계의 기업인 포세이다 세라퓨틱스사는 2023년 2월 3일자로 에릭 오스타 타그 의학 박사의 이사회장 사임과 이사 모임에서 퇴임을 발표했습니다. 그러나 오스터태그 박사는 컨설턴트로서 계속해서 당사에 공헌하고 기술적, 과학적 사항에 관하여 귀중한 전문지식을 제공합니다.

목차

제1장 BCMA 표적 요법 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 Bcma 표적 요법의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 BCMA 표적 치료 산업 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀의 분석

제5장 BCMA 표적 치료 시장 : COVID-19 감염의 영향 분석

  • 프리 COVID-19의 영향 분석
  • 포스트 COVID-19의 영향 분석

제6장 BCMA 표적 요법 시장 상황

  • BCMA 표적요법 시장 점유율 분석 : 2023년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥 기업의 분석

제7장 BCMA 표적 요법 시장 - 유형별

  • 개요
    • 유형별 부문 점유율 분석
    • 이중특이적 항체
    • 항체 약물 복합체
    • 키메라 항원 수용체 T 세포

제8장 BCMA 표적 치료 시장-암별

  • 개요
    • 암별 부문 점유율 분석
    • 간암
    • 호흡기 암
    • 뇌종양
    • 기타

제9장 BCMA 표적 치료 시장 - 최종 사용자별

  • 개요
    • 최종 사용자별 부문 점유율 분석
    • 병원
    • 암 연구

제10장 BCMA 표적 요법 시장-지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석-BCMA 표적 치료 산업

  • 경쟁 대시보드
  • 기업 프로파일
    • Transposagen Biopharmaceuticals
    • Sutro Biopharma
    • Malin Corporation
    • Eureka Therapeutics
    • firstVentury Equity
    • Five Prime Therapeutics
    • Credit Suisse Securities
    • Dana-Farber Cancer Institute
    • Deerfield Partners
    • Onyx Pharmaceuticals
    • Juno Therapeutics

제12장 애널리스트의 전방위 전망

BJH 24.02.13

REPORT HIGHLIGHT

Bcma Targeted Therapies Market size was valued at USD 9,010 Million in 2023, expanding at a CAGR of 20.5% from 2024 to 2032.

BCMA, or B cell maturation antigen, has emerged as a promising treatment target for multiple myeloma (MM) due to its highly specific expression in malignant plasma cells (PCs). Various BCMA-targeted therapies, such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have shown remarkable clinical responses in patients with relapsed and refractory MM. The introduction of novel therapeutics like proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has further enhanced the treatment outcomes for patients with MM. It is estimated that there will be over 275,000 new cases of multiple myeloma worldwide by 2040. Multiple myeloma is a type of blood cancer characterized by the abnormal proliferation of malignant plasma cells, primarily originating in the bone marrow. BCMA, a cell surface antigen predominantly found in multiple myeloma cases, presents a valuable target for therapeutic interventions in this disease.

Bcma Targeted Therapies Market- Market Dynamics

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

BCMA-targeted therapies, such as targeted treatments, provide a more precise method by specifically focusing on cancer cells that express BCMA. This approach has the potential to result in treatments that are more effective and less harmful, thereby addressing the unmet medical requirements. According to the American Society of Clinical Oncology, In 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the United States will be diagnosed with multiple myeloma. Worldwide, an estimated 176,404 people were diagnosed with multiple myeloma in 2020. Additionally, ongoing advancements in comprehending the molecular and genetic foundations of multiple myeloma may lead to the identification of new therapeutic targets and the development of more potent BCMA-targeted therapies. However, it is important to note that the high cost of these therapies may hinder market growth.

Bcma Targeted Therapies Market- Key Insights

  • As per the analysis shared by our research analyst, the global Bcma Targeted Therapies market is estimated to grow annually at a CAGR of around 20.5% over the forecast period (2024-2032)
  • Based on Type segmentation, Chimeric Antigen Receptor T-Cells was predicted to show maximum market share in the year 2023
  • Based on End-User segmentation, Hospitals was the leading type in 2023
  • On the basis of region, North America was the leading revenue generator in 2023

Bcma Targeted Therapies Market- Segmentation Analysis:

The Global Bcma Targeted Therapies Market is segmented on the basis of Type, Cancer, End-User, and Region.

The market is divided into three categories based on Type: Bispecific Antibodies, Antibody Drug Conjugates and Chimeric Antigen Receptor T-Cells.The market is largely dominated by the segment of Chimeric Antigen Receptor T-Cells. Multiple myeloma cells, which are a type of cancer that affects plasma cells, express a protein called BCMA on their surface. CAR-T cell therapy is an immunotherapy approach that involves modifying the patient's own T cells to express a chimeric antigen receptor (CAR) capable of identifying and attacking cancer cells.

The market is segmented into three groups according to the type of cancer: Liver Cancer, Respiratory Cancer, Brain Cancer, and Others. B-Cell Maturation Antigen (BCMA) targeted therapies have mainly been used in the treatment of multiple myeloma, a form of cancer that impacts plasma cells. BCMA is present on the surface of multiple myeloma cells, which makes it a prime target for therapeutic interventions.

The market is divided into two categories based on End-User: Hospitals and Cancer Research Institute. The market is largely controlled by the hospitals sector. In order to improve patient care and support services, hospitals may have to focus on managing the potential side effects of BCMA-targeted therapies and providing comprehensive care for patients receiving treatment. It is crucial for hospitals to comply with regulatory requirements for the administration of cancer treatments, ensuring that protocols are in line with the safety and efficacy standards set by health authorities.

Bcma Targeted Therapies Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing investments in research and development of innovative therapies for multiple myeloma. The United States serves as a major center for clinical research, hosting numerous clinical trials for various diseases, including multiple myeloma. The presence of renowned research institutions, academic medical centers, and biotechnology companies contributes to a strong infrastructure for conducting clinical trials, thereby facilitating the development of new therapies. According to the National Health Expenditures, the United States (U.S.) witnessed a significant increase in medical and health research and development (R&D) investment, reaching USD 245.1 billion in 2020, marking an 11.1% rise from 2019. The growth rates in the public-private sector R&D ecosystem underwent changes in 2020, likely influenced by the response to and impact of the COVID-19 pandemic.

Bcma Targeted Therapies Market- Competitive Landscape:

The BCMA-targeted therapies market is characterized by a dynamic competitive landscape, with numerous pharmaceutical and biotechnology companies actively engaged in the development of these treatments. These therapies have demonstrated clinical effectiveness in addressing multiple myeloma, particularly in patients who have relapsed or shown resistance to other treatment options. Many companies are currently involved in both preclinical and clinical stages of developing BCMA-targeted therapies, either as standalone treatments or in combination with other drugs. As an example, on January 31, 2023, Poseida Therapeutics, Inc., a clinical-stage company specializing in cell and gene therapy, announced the resignation of Dr. Eric Ostertag, M.D., Ph.D., as Executive Chairman and his retirement from the Board of Directors, effective February 3, 2023. However, Dr. Ostertag will continue to contribute to the company as a consultant, providing valuable expertise in technical and scientific matters.

Recent Developments:

November 17, 2022, More than 275,000 new cases of multiple myeloma are expected to occur globally by the year 2040. Multiple myeloma is a blood cancer characterized by the proliferation of malignant plasma cells that typically originate in the bone marrow. B-cell maturation antigen (BCMA) is an important cell surface antigen found in nearly all cases of multiple myeloma, but with limited expression on normal tissues other than plasma cells. This makes it a key target for multiple myeloma therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BCMA TARGETED THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposagen Biopharmaceuticals
  • Sutro Biopharma
  • Malin Corporation
  • Eureka Therapeutics
  • firstVentury Equity
  • Five Prime Therapeutics
  • Credit Suisse Securities
  • Dana-Farber Cancer Institute
  • Deerfield Partners
  • Onyx Pharmaceuticals
  • Juno Therapeutics

GLOBAL BCMA TARGETED THERAPIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bispecific Antibodies
  • Antibody Drug Conjugates
  • Chimeric Antigen Receptor T-Cells

GLOBAL BCMA TARGETED THERAPIES MARKET, BY CANCER- MARKET ANALYSIS, 2019 - 2032

  • Liver Cancer
  • Respiratory Cancer
  • Brain Cancer
  • Others

GLOBAL BCMA TARGETED THERAPIES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Research Institute

GLOBAL BCMA TARGETED THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bcma Targeted Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bcma Targeted Therapies Market Snippet by Type
    • 2.1.2. Bcma Targeted Therapies Market Snippet by Cancer
    • 2.1.3. Bcma Targeted Therapies Market Snippet by End-User
    • 2.1.4. Bcma Targeted Therapies Market Snippet by Country
    • 2.1.5. Bcma Targeted Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bcma Targeted Therapies Key Market Trends

  • 3.1. Bcma Targeted Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bcma Targeted Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bcma Targeted Therapies Market Opportunities
  • 3.4. Bcma Targeted Therapies Market Future Trends

4. Bcma Targeted Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bcma Targeted Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bcma Targeted Therapies Market Landscape

  • 6.1. Bcma Targeted Therapies Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bcma Targeted Therapies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Bispecific Antibodies
    • 7.1.3. Antibody Drug Conjugates
    • 7.1.4. Chimeric Antigen Receptor T-Cells

8. Bcma Targeted Therapies Market - By Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer, 2023 & 2032 (%)
    • 8.1.2. Liver Cancer
    • 8.1.3. Respiratory Cancer
    • 8.1.4. Brain Cancer
    • 8.1.5. Others

9. Bcma Targeted Therapies Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Research Institute

10. Bcma Targeted Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bcma Targeted Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bcma Targeted Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bcma Targeted Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bcma Targeted Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bcma Targeted Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bcma Targeted Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Transposagen Biopharmaceuticals
    • 11.2.2. Sutro Biopharma
    • 11.2.3. Malin Corporation
    • 11.2.4. Eureka Therapeutics
    • 11.2.5. firstVentury Equity
    • 11.2.6. Five Prime Therapeutics
    • 11.2.7. Credit Suisse Securities
    • 11.2.8. Dana-Farber Cancer Institute
    • 11.2.9. Deerfield Partners
    • 11.2.10. Onyx Pharmaceuticals
    • 11.2.11. Juno Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제